Patent · US Active

T cell receptors recognizing MHC class II-restricted MAGE-A3

US9879065B2 · kind B2 · utility

3Cited by

10References

35Claims

0Family size

Assignee

The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

Paul F. Robbins · Silver Spring, US
Steven A. Rosenberg · Potomac, US
Xin Yao · Beijing, CN

Key dates

Filing date	Sep 13, 2013
Grant date	Jan 30, 2018
Priority date	—
Expiry date	Dec 10, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/7051
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.